Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway - BioSpace
Summit Therapeutics is teaming up with pharma giants AstraZeneca and Daiichi Sankyo for a new clinical trial collaboration. The partnership will explore combining ivonescimab with datopotamab deruxtecan, initially focusing on first-line triple-negative breast cancer.
- Summit Therapeutics enters a clinical trial collaboration with AstraZeneca and Daiichi Sankyo.
- The partnership will investigate the combination of ivonescimab and datopotamab deruxtecan.
- Initial focus is a Phase III study in first-line triple-negative breast cancer.
- The collaboration expands Summit's development program into breast cancer and other solid tumors.
This collaboration marks a significant step for Summit Therapeutics as they expand their research into breast cancer treatment. By partnering with established companies like AstraZeneca and Daiichi Sankyo, Summit gains access to valuable resources and expertise for their investigational drug, ivonescimab.
The focus of this new venture is to evaluate the combined efficacy of ivonescimab, a bispecific antibody targeting PD-1 and VEGF, with datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate. This combination aims to create a more potent therapeutic approach for various solid tumors.
The initial phase of the collaboration will involve a Phase III study targeting first-line triple-negative breast cancer. This specific cancer type is known for its aggressive nature and limited treatment options, making innovative therapies like this combination highly anticipated. The agreement also opens the door for exploring the combination in other solid tumor settings, suggesting a broader potential impact.
This summary is an original, AI-generated overview based on publicly available information. All rights to the original article or video remain with the source publisher.